Public Employees Retirement System of Ohio increased its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 88.3% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 106,384 shares of the biopharmaceutical company’s stock after purchasing an additional 49,897 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.12% of Inovio Pharmaceuticals worth $834,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of INO. Vanguard Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after purchasing an additional 226,861 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $1,411,000. GSA Capital Partners LLP purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $1,035,000. Virtu KCG Holdings LLC purchased a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $556,000. Finally, Credit Suisse AG boosted its position in shares of Inovio Pharmaceuticals by 108.6% during the 1st quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 69,068 shares during the period. 25.04% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) Shares Bought by Public Employees Retirement System of Ohio” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-shares-bought-by-public-employees-retirement-system-of-ohio/1695205.html.

Shares of Inovio Pharmaceuticals, Inc. (INO) opened at $4.74 on Friday. Inovio Pharmaceuticals, Inc. has a 1 year low of $4.40 and a 1 year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.15). The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. Inovio Pharmaceuticals’s revenue for the quarter was down 79.2% on a year-over-year basis. During the same period last year, the firm posted ($0.28) earnings per share. equities research analysts predict that Inovio Pharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

A number of equities analysts recently weighed in on the stock. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a research report on Thursday. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Royal Bank Of Canada began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $19.16.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.